Connetics and Relaxin

Connetics and Relaxin: "

Presents Connetics, a biotechnology and pharmaceutical company, from its founding in 1993 through the final clinical trials of its flagship drug compound in 2000. Throughout that time, the company had experienced the failure of another compound, while successfully in-licensing other pharmaceutical products that would immediately generate income. Ultimately, the pivotal trial in 2000 was a failure, and CEO Tom Wiggans must manage the company through this failure (the stock went from about $25 to $5 after the results were revealed publicly).

Learning Objective: To examine issues associated with biotechnology finance and strategy, and to address the challenges of managing through crises and making difficult strategic decisions with imperfect information.

"